IBD-RESPONSE is a cutting-edge precision medicine study, which will develop and validate a predictive algorithm for response or failure to respond to biologic or janus kinase (JAK) inhibitor therapies for Crohn's disease and ulcerative colitis.
We hope findings from IBD-RESPONSE will lead to new personalised avenues for IBD treatment through discovery and validation of predictive tools that may be either incorporated in clinical practice or further tested in stratified clinical trials.
IBD-RESPONSE will provide a better understanding of the relationship between the gut microbiome and treatment outcomes in IBD, and may help to identify novel treatment targets or mechanisms to modify microbes within the gut to improve treatment responsiveness.
Our aim is for the study to support precision medicine in Crohn's disease and ulcerative colitis by enabling clinicians in the future to select the best treatment for each individual patient.
